Photo from wikipedia
Nivolumab is an immune checkpoint inhibitor (ICI) that facilitates T cell activation, which results in great efficacy in melanoma (1, 2). The dosage originally approved worldwide was 2-3 mg/kg or… Click to show full abstract
Nivolumab is an immune checkpoint inhibitor (ICI) that facilitates T cell activation, which results in great efficacy in melanoma (1, 2). The dosage originally approved worldwide was 2-3 mg/kg or 240 mg/body every two-three weeks (LOW-dose regimen). In 2020, a new dosage regimen of 480 mg/body of nivolumab every four weeks (HIGH-dose regimen) was approved in Japan.
Keywords:
serious immune;
may induce;
induce serious;
immune related;
nivolumab may;
dosing nivolumab
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!